Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information
PALO ALTO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq:SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today provided certain preliminary unaudited financial results for gross and net sales for the fiscal year ended December 31, 2023, based on currently available information.
Related news for (SCLX)
- MoBot’s Stock Market Highlights – 03/03/25 04:00 PM
- Today’s Top Performers: MoBot’s Market Review 03/03/25 03:00 PM
- Denali Capital Acquisition Corp and Scilex Holding’s Semnur Pharmaceuticals Sign LOI for Proposed Business Combination
- Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024